Harvard Bioscience financials
$7.96−0.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $86.5M | $94.1M | $112.3M | $113.3M | $118.9M | $102.1M | $116.2M | $120.8M | $77.4M | $104.5M |
| Gross profit | $49.9M | $54.8M | $66.1M | $60.8M | $67.7M | $58.0M | $64.3M | $63.2M | $39.2M | $48.4M |
| Gross margin | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% | 56.8% | 55.4% | 52.3% | 50.6% | 46.3% |
| Operating income | -$48.6M | -$6.2M | $1.9M | -$6.9M | $2.1M | $221.0K | $377.0K | $984.0K | -$635.0K | -$1.8M |
| Net income | -$56.7M | -$12.4M | -$3.4M | -$9.5M | -$288.0K | -$7.8M | -$4.7M | -$2.9M | -$865.0K | -$4.3M |
| Net margin | −65.5% | −13.2% | −3.0% | −8.4% | −0.2% | −7.6% | −4.0% | −2.4% | −1.1% | −4.1% |
| Diluted EPS | $-12.80 | $-2.80 | $-0.80 | $-2.30 | $-0.10 | $-2.00 | $-1.20 | $-0.80 | $-0.20 | $-1.30 |
| EBITDA | $5.3M | $946.0K | $8.9M | $409.0K | $9.7M | $7.9M | $9.6M | $8.8M | $3.1M | $3.1M |
| Operating cash flow | $6.7M | $1.4M | $14.0M | $1.2M | $1.3M | $9.3M | $8.0M | $2.9M | $1.1M | $5.4M |
| Free cash flow | $5.5M | -$1.2M | $12.2M | -$438.0K | $67.0K | $8.2M | $6.8M | $1.9M | $167.0K | $3.9M |
| Diluted shares | 4.4M | 4.4M | 4.2M | 4.1M | 4.0M | 3.9M | 3.8M | 3.6M | 3.5M | 3.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.6M | $4.1M | $4.3M | $4.5M | $7.8M | $8.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $35.9M | $37.0M | $36.6M | $46.8M | $48.3M | $48.0M |
| Total assets | $80.1M | $126.6M | $137.4M | $145.4M | $162.3M | $156.3M |
| Total liabilities | $66.3M | $63.3M | $64.3M | $73.1M | $78.9M | $79.6M |
| Shareholders' equity | $13.7M | $63.3M | $73.1M | $72.2M | $83.4M | $76.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology